Skip to main content
Skip main navigationClose Drawer MenuOpen Drawer Menu
Sections

Corresponding Author

  • 1. Pal S., Gong J., Mhatre S.K., et al. "Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database". BMC Cancer 2019;19:548.

    CrossrefMedlineGoogle Scholar
  • 2. Michaelson M.D., Gupta S., Agarwal N., et al. "A phase Ib study of axitinib in combination with crizotinib in patients with metastatic renal cell cancer or other advanced solid tumors". Oncologist 2019Jun6. [E-pub ahead of print].

    CrossrefGoogle Scholar
  • 3. Li J., Xu J., Chen Y., Zhang J., Cao Y., Lu P. "Efficacy comparison of intravitreal anti-VEGF therapy for three subtypes of neovascular age-related macular degeneration: a systematic review and meta-analysis". J Ophthalmol 2018;2018:1425707.

    CrossrefMedlineGoogle Scholar
  • 4. Malecic N., Young H.S. "Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis". Expert Opin Investig Drugs 2016;25:455-462.

    CrossrefMedlineGoogle Scholar
  • 5. Robinson E.S., Matulonis U.A., Ivy P., et al. "Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor". Clin J Am Soc Nephrol 2010;5:477-483.

    CrossrefMedlineGoogle Scholar
  • 6. Touyz R.M., Lang N.N., Herrmann J., van den Meiracker A.H., Danser A.H.J. "Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition". Hypertension 2017;70:220-226.

    CrossrefMedlineGoogle Scholar
  • 7. Humphreys B.D., Atkins M.B. "Rapid development of hypertension by sorafenib: toxicity or target?"Clin Cancer Res 2009;15:5947-5949.

    CrossrefMedlineGoogle Scholar
  • 8. Williams B., Spiering W., Agabiti Rosei E., et al. "2018 ESC/ESH Guidelines for the management of arterial hypertension". Eur Heart J 2018;39:3021-3104.

    CrossrefMedlineGoogle Scholar
  • 9. Whelton P.K., Carey R.M., Aronow W.S., et al. "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". [published correction appears in J Am Coll Cardiol 2018;71:2275–9]J Am Coll Cardiol 2018;71:e127-e248.

    View ArticleGoogle Scholar
  • 10. Dobbin S.J.H., Cameron A.C., Petrie M.C., Jones R.J., Touyz R.M., Lang N.N. "Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors". Heart 2018;104:1995-2002.

    CrossrefMedlineGoogle Scholar
  • 11. Hanna R.M., Lopez E.A., Hasnain H., et al. "Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension". Clin Kidney J 2019;12:92-100.

    CrossrefMedlineGoogle Scholar
  • 12. Hanna R.M., Barsoum M., Arman F., Selamet U., Hasnain H., Kurtz I. "Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence". Kidney Int 2019;96:572-580.

    CrossrefMedlineGoogle Scholar
  • 13. Rasier R., Artunay O., Yuzbasioglu E., Sengul A., Bahcecioglu H. "The effect of intravitreal bevacizumab (Avastin) administration on systemic hypertension". Eye (Lond) 2009;23:1714-1718.

    CrossrefMedlineGoogle Scholar
  • 14. Maitland M.L., Bakris G.L., Black H.R., et al.Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee. "Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors". J Natl Cancer Inst 2010;102:596-604.

    CrossrefMedlineGoogle Scholar
  • 15. Waliany S., Sainani K.L., Park L.S., Zhang C.A., Srinivas S., Witteles R.M. "Increase in blood pressure associated with tyrosine kinase inhibitors targeting vascular endothelial growth factor". J Am Coll Cardiol CardioOnc 2019;1:24-36.

    View ArticleGoogle Scholar
  • 16. Bottinor W.J., Shuey M.M., Manouchehri A., et al. "Renin-angiotensin-aldosterone system modulates blood pressure response during vascular endothelial growth factor receptor inhibition". J Am Coll Cardiol CardioOnc 2019;1:14-23.

    View ArticleGoogle Scholar
  • 17. Belcik J.T., Qi Y., Kaufmann B.A., et al. "Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer". J Am Coll Cardiol 2012;60:618-625.

    View ArticleGoogle Scholar
  • 18. Kappers M.H., van Esch J.H., Sluiter W., Sleijfer S., Danser A.H., van den Meiracker A.H. "Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels". Hypertension 2010;56:675-681.

    CrossrefMedlineGoogle Scholar
  • 19. Facemire C.S., Nixon A.B., Griffiths R., Hurwitz H., Coffman T.M. "Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression". Hypertension 2009;54:652-658.

    CrossrefMedlineGoogle Scholar